Comparing the Effectiveness and Costs of Bevacizumab to Ranibizumab in Patients With Retinal Vein Occlusions (BRVO)

NCT01635803 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

296

Enrollment

OTHER

Sponsor class

Conditions

Retinal Vein Occlusion

Interventions

DRUG: Bevacizumab
DRUG: Ranibizumab

Sponsor

Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

Collaborators

[object Object]
[object Object]
[object Object]
[object Object]
[object Object]
[object Object]